We have recently shown that treating neuroblastoma SH-SY5Y cells with the GIVA cPLA2 inhibitor GK200 reduced the level of arachidonic acid, resulting in a remarkable reduction in the levels of both oligomeric and monomeric α-synuclein, and thus promoting neuronal cell survival [21]. This evidence concerns the gene PLA2G4A and neuroblastoma.